Incyte’s Strategic Acquisition: A Premature and Costly Move Amid Patent Cliff Concerns
TipRanks (Tue, 23-Apr 7:05 PM ET)
Incyte (INCY) Gets a Buy from Piper Sandler
TipRanks (Tue, 23-Apr 3:25 PM ET)
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Benzinga (Tue, 23-Apr 3:03 PM ET)
Incyte to acquire immune-focused drug developer Escient
Seeking Alpha News (Tue, 23-Apr 7:31 AM ET)
Business Wire (Tue, 23-Apr 7:00 AM ET)
Top high growth investment ratio stocks from each sector - GS
Seeking Alpha News (Mon, 22-Apr 4:25 PM ET)
Goldman picks top capex and R&D stocks
Seeking Alpha News (Sun, 21-Apr 2:42 PM ET)
Top 10 most oversold S&P 500 stocks
Seeking Alpha News (Fri, 19-Apr 11:56 AM ET)
Incyte to Report First Quarter Financial Results
Business Wire (Thu, 11-Apr 8:00 AM ET)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Incyte trades on the NASDAQ stock market under the symbol INCY.
As of April 23, 2024, INCY stock price declined to $51.65 with 2,218,262 million shares trading.
INCY has a beta of 0.88, meaning it tends to be less sensitive to market movements. INCY has a correlation of 0.18 to the broad based SPY ETF.
INCY has a market cap of $11.60 billion. This is considered a Large Cap stock.
Last quarter Incyte reported $1 billion in Revenue and $1.06 earnings per share. This beat revenue expectation by $13 million and missed earnings estimates by -$.10.
In the last 3 years, INCY stock traded as high as $88.26 and as low as $50.27.
The top ETF exchange traded funds that INCY belongs to (by Net Assets): VTI, VOO, VO, SPY, USMV.
INCY has underperformed the market in the last year with a price return of -30.8% while the SPY ETF gained +24.3%. INCY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.0% and -6.2%, respectively, while the SPY returned +4.9% and -2.5%, respectively.
INCY support price is $51.25 and resistance is $52.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INCY stock will trade within this expected range on the day.